Active	Status	Sponsor type	Region	Phase	Filter
8 Active 8 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yu, Xian-Jun
NCT04217096: Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients	Not yet recruiting	4	40	RoW	Paclitaxel liposome, S-1	Fudan University	Advanced Pancreatic Cancer	09/22	03/23
NCT04617821: AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer	Recruiting	3	300	RoW	Nab paclitaxel plus gemcitabine, AG regimen, mFOLFIRINOX, modified FOLFIRINOX regimen	Fudan University	Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma	09/24	09/24
NCT04581876: The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer	Recruiting	2	120	RoW	raltitrexed for injection, raltitrexed, nab-paclitaxel, albumin-bound paclitaxel	Fudan University	Pancreatic Cancer, Chemotherapy Effect	09/22	03/23
NCT04498689: Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer	Recruiting	2	117	RoW	Camrelizumab, Nab paclitaxel, Albumin paclitaxl, Gemcitabine Injection, Gemcitabine	Fudan University	Metastatic Pancreatic Cancer	12/22	12/22
NCT03403101: The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer	Recruiting	2	65	RoW	S1, Oxaliplatin, Irinotecan	Fudan University	Carcinoma, Pancreatic Ductal	12/23	07/24
NCT06166147: A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection	Recruiting	N/A	276	RoW		Fudan University, Shanghai Weihe Medical Laboratory Co., Ltd.	Pancreatic Cancer	10/26	03/27
NCT06456281: Multi-omics Model for Pancreatic Cancer Screening Using cfDNA	Recruiting	N/A	480	RoW	A noninvasive cfDNA multi-omics assay	Fudan University, Nanjing Simcere Medical Laboratory Science Co., Ltd.	Pancreatic Cancer	03/25	12/25
NCT04620577: The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice	Recruiting	N/A	120	RoW	antibiotic	Xian-Jun Yu	The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice	06/23	06/23
Luo, Guo-Pei
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yu, Xian-Jun
NCT04217096: Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients	Not yet recruiting	4	40	RoW	Paclitaxel liposome, S-1	Fudan University	Advanced Pancreatic Cancer	09/22	03/23
NCT04617821: AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer	Recruiting	3	300	RoW	Nab paclitaxel plus gemcitabine, AG regimen, mFOLFIRINOX, modified FOLFIRINOX regimen	Fudan University	Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma	09/24	09/24
NCT04581876: The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer	Recruiting	2	120	RoW	raltitrexed for injection, raltitrexed, nab-paclitaxel, albumin-bound paclitaxel	Fudan University	Pancreatic Cancer, Chemotherapy Effect	09/22	03/23
NCT04498689: Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer	Recruiting	2	117	RoW	Camrelizumab, Nab paclitaxel, Albumin paclitaxl, Gemcitabine Injection, Gemcitabine	Fudan University	Metastatic Pancreatic Cancer	12/22	12/22
NCT03403101: The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer	Recruiting	2	65	RoW	S1, Oxaliplatin, Irinotecan	Fudan University	Carcinoma, Pancreatic Ductal	12/23	07/24
NCT06166147: A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection	Recruiting	N/A	276	RoW		Fudan University, Shanghai Weihe Medical Laboratory Co., Ltd.	Pancreatic Cancer	10/26	03/27
NCT06456281: Multi-omics Model for Pancreatic Cancer Screening Using cfDNA	Recruiting	N/A	480	RoW	A noninvasive cfDNA multi-omics assay	Fudan University, Nanjing Simcere Medical Laboratory Science Co., Ltd.	Pancreatic Cancer	03/25	12/25
NCT04620577: The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice	Recruiting	N/A	120	RoW	antibiotic	Xian-Jun Yu	The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice	06/23	06/23
Luo, Guo-Pei
No trials found